Akcije

Archive of Oncology
kako citirati ovaj članak
podeli ovaj članak

Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:5
  • preuzimanja u poslednjih 30 dana:2

Sadržaj

članak: 1 od 37  
Back povratak na rezultate
2019, vol. 25, br. 2, str. 22-24
Dual checkpoint inhibitor induced autoimmune encephalitis
(naslov ne postoji na srpskom)
Maimonides Medical Center, Department of Medicine, Brooklyn, New York, USA
Ključne reči: Immunity; Encephalitis; Autoimmunity; PD-1 monoclonal antibody, CTLA-4 monoclonal antibody; Metastatic Cancer
Sažetak
(ne postoji na srpskom)
Immune checkpoint inhibitor therapy has become increasingly more used as a treatment modality for solid organ tumors. Nivolumab, anti-PD-1 and Ipilimumab, anti-CTLA-4 monoclonal antibodies are checkpoint inhibitors with well described immune related toxicities. Immune specific neurotoxicity is rare and not well elucidated in literature. We present a case of severe autoimmune encephalitis in a patient with metastatic renal cell carcinoma treated with both Nivolumab and Ipilimumab. A 53-year-old man with metastatic renal cell carcinoma presented due to visual and auditory hallucinations of sudden onset, confusion and weakness. Initial imaging and diagnostic workup did not demonstrate a clear source. However, a neurological etiology was suspected. It was concluded that the patient had autoimmune encephalitis induced by dual check point inhibitor therapy. This was further strengthened by his rapid response to systemic corticosteroid therapy. We present a summary of this case and its management and a review of literature on dual checkpoint inhibitor induced neurological adverse effects.
Reference
Bellmunt, J., de Wit, R., Vaughn, D.J., Fradet, Y., Lee, J., Fong, L., Vogelzang, N.J., Climent, M.A., Petrylak, D.P., Choueiri, T.K., Necchi, A., Gerritsen, W., Gurney, H., Quinn, D.I., Culine, S. (2017) Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. New England Journal of Medicine, 376(11): 1015-1026
Bot, I., Blank, C.U., Boogerd, W., Brandsma, D. (2013) Neurological immune-related adverse events of ipilimumab. Practical Neurology, 13(4): 278-280
Brahmer, J., Reckamp, K.L., Baas, P., Crinò, L., Eberhardt, W.E.E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E.E., Holgado, E., Waterhouse, D., Ready, N., Gainor, J., Arén, F.O., Havel, L. (2015) Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. New England Journal of Medicine, 373(2): 123-135
Cuzzubbo, S., Javeri, F., Tissier, M., Roumi, A., Barlog, C., Doridam, J., Lebbe, C., Belin, C., Ursu, R., Carpentier, A.F. (2017) Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. European Journal of Cancer, 73: 1-8
Decatris, M.P., o'Byrne Kenneth, J. (2016) Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer. Future Oncology, 12(15): 1805-1822
Feng, S., Coward, J., McCaffrey, E., Coucher, J., Kalokerinos, P., o’Byrne Ken (2017) Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors. Journal of Thoracic Oncology, 12(11): 1626-1635
Graus, F., Saiz, A., Dalmau, J. (2010) Antibodies and neuronal autoimmune disorders of the CNS. Journal of Neurology, 257(4): 509-517
Kao, J.C., Liao, B., Markovic, S.N., Klein, C.J., Naddaf, E., Staff, N.P., Mauermann, M.L. (2017) Neurological Complications Associated with Anti-Programmed Death 1 (PD-1) Antibodies. JAMA Neurology, 1(10): 1216-1216
Liao, B., Shroff, S., Kamiya-Matsuoka, C., Tummala, S. (2014) Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro-Oncology, 16(4): 589-593
Maur, M., Tomasello, C., Frassoldati, A., Dieci, M.V., Barbieri, E., Conte, P. (2012) Posterior Reversible Encephalopathy Syndrome During Ipilimumab Therapy for Malignant Melanoma. Journal of Clinical Oncology, 30(6): e76-e78
Motzer, R.J., Escudier, B., McDermott, D.F., George, S., Hammers, H.J., Srinivas, S., Tykodi, S.S., Sosman, J.A., Procopio, G., Plimack, E.R., Castellano, D., Choueiri, T.K., Gurney, H., Donskov, F. (2015) Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 373(19): 1803-1813
Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., Daud, A., Carlino, M.S., McNeil, C., Lotem, M., Larkin, J., Lorigan, P., Neyns, B., Blank, C.U., Hamid, O., Mateus, C. (2015) Pembrolizumab versus Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 372(26): 2521-2532
Salam, S., Lavin, T., Turan, A. (2016) Limbic encephalitis following immunotherapy against metastatic malignant melanoma. BMJ Case Reports, bcr2016215012-bcr2016215012
Seiwert, T.Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., Eder, J.P., Chow, L.Q. (2016) Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial. Lancet Oncology, 17(7): 30066-30069
Spain, L., Walls, G., Julve, M., o'Meara K., Schmid, T., Kalaitzaki, E., Turajlic, S., Gore, M., Rees, J., Larkin, J. (2016) Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: A single centre experience and review of the literature. Annals of Oncology, 28: mdw558-mdw558
Wei, X., Walia, V., Lin, J.C., Teer, J.K., Prickett, T.D., Gartner, J., Davis, S., Stemke-Hale, K., Davies, M.A., Gershenwald, J.E., Robinson, W., Robinson, S., Rosenberg, S.A., Samuels, Y. (2011) Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nature Genetics, 43(5): 442-446
Wilgenhof, S., Neyns, B. (2011) Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient. Annals of Oncology, 22(4): 991-993
Williams, T.J., Benavides, D.R., Patrice, K., Dalmau, J.O., de Ávila, A.L.R., Le, D.T., Lipson, E.J., Probasco, J.C., Mowry, E.M. (2016) Association of Autoimmune Encephalitis with Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer. JAMA Neurology, 73(8): 928-928
 

O članku

jezik rada: engleski
vrsta rada: prikaz slučaja
DOI: 10.2298/AOO181230003E
objavljen u SCIndeksu: 29.07.2019.
metod recenzije: jednostruko anoniman
Creative Commons License 4.0

Povezani članci

Nema povezanih članaka